Here's a glimpse of the most anticipated cardiovascular event of the year - the ESC Congress 2016. The primary results of 30 novel clinical trials will be presented, with findings revealed in advance to the media in six dedicated press conferences.
Be the first to hear the results of REVERSE II,
a multi-national validation of a clinical decision rule to identify low
risk unprovoked venous thromboembolism patients who can discontinue
anticoagulants.
Find out
whether direct or selective catheterisation guided by coronary computed
tomography (CT) is the preferred choice in patients with stable
suspected coronary artery disease from the findings of the randomised CONSERVE trial.
Also in the
area of imaging, discover the outcome of the first head-to-head
comparison of coronary CT angiography, myocardial perfusion SPECT, PET,
and hybrid imaging for diagnosis of ischaemic heart disease in the PACIFIC trial. And get the answer to the question “Does Optical Coherence Tomography Optimise Results of Stenting?” in the randomised DOCTORS trial.
Exciting new science will be presented in the field of coronary stenting. ANTARCTIC
will demonstrate whether platelet monitoring for dose adjustment of
antiplatelet drugs is superior to a conventional fixed dose in elderly
patients stented for an acute coronary syndrome. The results of a
randomised comparison of ticagrelor and prasugrel in ST-segment
elevation myocardial infarction will be unveiled in PRAGUE -18.
Don’t miss the randomised phase III trial results from ESCAPE
on the effect of alirocumab on the frequency of lipoprotein apheresis,
which removes low density lipoprotein (LDL) cholesterol from the blood.
Journalists will learn the latest prevention strategies in sleep apnoea (SAVE
trial), and resistant hypertension, where outcomes with the novel
median nerve modulation technique will be presented. Methods for cardiac
rehabilitation have been compared in arandomised, controlled superiority trial of an educational and behavioral intervention and the results from OPTICARE will be released for the first time.
Innovative approaches for the treatment of heart failure will be divulged in DANISH,
a randomised, controlled trial which examined the effect of an
implantable cardioverter defibrillator on mortality in patients with
non-ischaemic systolic heart failure.
This is just a
small taste of the groundbreaking research that will be presented in
this year’s hot lines. Additional late breaking science will presented
in 25 clinical trial updates, 24 registries and 12 basic and
translational hot lines presentations.
Four press conferenceswill
be held on topics of interest to the press: the cardiovascular risks of
modern life, stroke and arrhythmia, heart failure, and preventing
sudden death with diet and devices.
Source: ESC
Image Credit: ESC
